The Los Angeles-based company, founded in 2015, is focused on researching and developing proprietary drug treatments for central nervous system disorders. Their peptide treatments have shown promise in regulating stress-induced anxiety and restoring neurotransmitter levels. Glauser Life Sciences is currently considering the release of formulations for anxiety relief, sobriety assistance/management, cognitive enhancement, and improved sleep function. Their mission is to develop a range of innovative treatments, including preemptive care, for CNS disorders.